Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MDH2 | P40926 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.55 |
| ▸ | CTSV | O60911 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.54 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21924233 | 0.94 | MAOB (0.60) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL7907913 | 0.91 | NR4A2 (0.60) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL7908630 | 0.91 | NR4A2 (0.60) | MAOBNR4A2MCL1KMT2AFOLH1 | |
| SCHEMBL7908820 | 0.91 | NR4A2 (0.60) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL7900610 | 0.91 | RAB9A (0.58) | MAOBMCL1FOLH1SMN1; SMN2KDM4E | |
| SCHEMBL7914070 | 0.91 | MAOB (0.55) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL1448026 | 0.91 | MAOB (0.61) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL7901056 | 0.90 | MRGPRX4 (0.61) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL16016781 | 0.90 | MAOB (0.63) | MAOBNR4A2NR4A1NR4A3MCL1 | |
| SCHEMBL7908069 | 0.90 | FFAR1 (0.55) | MAOBNR4A2NR4A1NR4A3MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0728128-B1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE POULENC RORER LTD (GB) | 1998-09-16 | — | — | EP | claimed |
| EP-0728128-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1996-08-28 | — | — | EP | claimed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | claimed |
| EP-3710462-B1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LTD (NZ) | 2026-05-13 | — | — | EP | disclosed |
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| US-11510980-B2 | Brartemicin analogues | VICTORIA LINK LTD. (NZ) | 2022-11-29 | — | — | US | disclosed |
| US-20210177965-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2021-06-17 | — | — | US | disclosed |
| US-20210177965-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2021-06-17 | — | — | US | disclosed |
| EP-3710462-A1 | BRARTEMICIN ANALOGUES | Victoria Link Limited (NZ) | 2020-09-23 | — | — | EP | disclosed |
| EP-0836592-A1 | AZEPANES AND THEIR RING HOMOLOGUES FOR THERAPY AND PROPHYLAXIS OF PROTEIN KINASE MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002249-A1 | NOVEL AZEPANES AND THEIR RING HOMOLOGUES FOR THERAPY AND PROPHYLAXIS OF PROTEIN KINASE MEDIATED DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-23 | — | — | WO | disclosed |
| EP-0728128-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
| US-4990511-A | Amide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-05 | — | — | US | disclosed |
| US-4990614-A | N-heterocyclic amides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-05 | — | — | US | disclosed |
| EP-0353753-A1 | Amide compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
| EP-0311517-A2 | Amide compound having glutamate receptor inhibiting activity | Takeda Chemical Industries, Ltd. (JP) | 1989-04-12 | — | — | EP | disclosed |
| US-4146631-A | ANTIALLERGENS, RESPIRATORY DISORDERS | MAY & BAKER LIMITED (GB) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, RXFP4 | MAOB 4572/4885NR4A2 712/4885NR4A1 1144/4885 |
| US-20210177965-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, CMKLR1 | MAOB 4537/4885NR4A2 905/4885NR4A1 1320/4885 |
| US-11510980-B2 | Brartemicin analogues | RXFP1, RXFP2, CMKLR1 | MAOB 4537/4885NR4A2 905/4885NR4A1 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.